Table 2 Univariate analysis according to baseline clinical parameters
From: A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
| OS, mo* | 95% CI | P | ||
|---|---|---|---|---|
| Previous gastrectomy | No | 6.7 | 5.3 to 8.2 | .660 |
| Yes | 6.7 | |||
| Gender | Male | 7.1 | 5.9 to 8.4 | .464 |
| Female | 6.6 | 5.9 to 7.3 | ||
| Age | < median | 7.1 | 5.9 to 8.4 | .243 |
| ≥ median | 6.5 | 5.9 to 7.3 | ||
| Response to first-line chemotherapy | No | 6.4 | 5.5 to 7.2 | .432 |
| Yes | 7.1 | 5.9 to 8.4 | ||
| Treatment-free interval | < median | 6.7 | 5.8 to 7.6 | .863 |
| ≥ median | 6.8 | 5.4 to 8.1 | ||
| Performance status | 0 or 1 | 7.1 | 6.2 to 8.1 | .001 |
| ≥ 2 | 5.4 | 3.8 to 7.1 | ||
| Albumin | < median | 6.5 | 5.2 to 7.5 | .553 |
| ≥ median | 7.1 | 5.9 to 8.3 | ||
| Alkaline phosphatase | < median | 6.5 | 5.7 to 7.4 | .886 |
| ≥ median | 7.1 | 5.6 to 8.6 | ||
| Bilirubin | < median | 6.2 | 5.3 to 7.1 | .766 |
| ≥ median | 7.1 | 5.9 to 8.4 | ||
| Calcium | < median | 7.2 | 6.0 to 8.3 | .210 |
| ≥ median | 5.9 | 5.1 to 6.8 | ||
| Hemoglobin | < median | 5.8 | 5.6 to 6.4 | .004 |
| ≥ median | 8.1 | 7.1 to 9.1 | ||
| No. of involved site(s) | 1 | 6.7 | 5.5 to 8.0 | .225 |
| ≥ 2 | 6.4 | 5.4 to 7.3 | ||
| Liver metastasis | No | 7.4 | 5.2 to 9.6 | .497 |
| Yes | 6.6 | 5.8 to 7.5 | ||
| Bone metastasis | No | 8.4 | 5.2 to 11.6 | .793 |
| Yes | 6.6 | 5.9 to 7.4 | ||
| Ascites | No | 7.1 | 6.2 to 8.1 | .038 |
| Yes | 4.7 | 3.5 to 5.9 | ||
| Bone marrow involvement | No | 6.7 | 5.9 to 7.6 | .555 |
| Yes | 5.0 | 2.5 to 7.6 | ||
| Weight loss | No | 6.7 | 5.8 to 7.5 | .853 |
| Yes | 6.6 | 3.4 to 9.9 |